CN119930820A - 抗ctla-4结合蛋白及其使用方法 - Google Patents

抗ctla-4结合蛋白及其使用方法 Download PDF

Info

Publication number
CN119930820A
CN119930820A CN202510014877.4A CN202510014877A CN119930820A CN 119930820 A CN119930820 A CN 119930820A CN 202510014877 A CN202510014877 A CN 202510014877A CN 119930820 A CN119930820 A CN 119930820A
Authority
CN
China
Prior art keywords
seq
cdr3
cdr1
cdr2
ctla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510014877.4A
Other languages
English (en)
Chinese (zh)
Inventor
D·S·约翰逊
A·S·阿德勒
R·A·米兹拉希
林咏雯
M·艾森修
E·L·斯通
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gigagen Inc
Original Assignee
Gigagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gigagen Inc filed Critical Gigagen Inc
Publication of CN119930820A publication Critical patent/CN119930820A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202510014877.4A 2018-12-27 2019-12-27 抗ctla-4结合蛋白及其使用方法 Pending CN119930820A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862785659P 2018-12-27 2018-12-27
US62/785,659 2018-12-27
PCT/US2019/068820 WO2020140084A1 (en) 2018-12-27 2019-12-27 Anti-ctla-4 binding proteins and methods of use thereof
CN201980092796.9A CN114008071B (zh) 2018-12-27 2019-12-27 抗ctla-4结合蛋白及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980092796.9A Division CN114008071B (zh) 2018-12-27 2019-12-27 抗ctla-4结合蛋白及其使用方法

Publications (1)

Publication Number Publication Date
CN119930820A true CN119930820A (zh) 2025-05-06

Family

ID=71126610

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510014877.4A Pending CN119930820A (zh) 2018-12-27 2019-12-27 抗ctla-4结合蛋白及其使用方法
CN201980092796.9A Active CN114008071B (zh) 2018-12-27 2019-12-27 抗ctla-4结合蛋白及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980092796.9A Active CN114008071B (zh) 2018-12-27 2019-12-27 抗ctla-4结合蛋白及其使用方法

Country Status (12)

Country Link
US (1) US12421311B2 (https=)
EP (1) EP3902821A4 (https=)
JP (2) JP7558949B2 (https=)
KR (1) KR20210121045A (https=)
CN (2) CN119930820A (https=)
AU (2) AU2019413366B2 (https=)
BR (1) BR112021012588A2 (https=)
CA (2) CA3124961C (https=)
IL (2) IL284156B2 (https=)
MX (1) MX2021007848A (https=)
SG (1) SG11202106764YA (https=)
WO (1) WO2020140084A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3002957A1 (en) * 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
AU2019413366B2 (en) 2018-12-27 2025-06-05 Gigagen, Inc. Anti-CTLA-4 binding proteins and methods of use thereof
CA3184082A1 (en) * 2020-07-02 2022-01-06 David Scott Johnson Anti-ctla-4 binding proteins and methods of use thereof
JP2024502035A (ja) * 2020-12-31 2024-01-17 ノヴァロック バイオセラピューティクス， リミテッド Ｔｎｆｒ２に対する抗体およびそれの使用
WO2023279068A1 (en) * 2021-07-02 2023-01-05 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
AU2022407541A1 (en) * 2021-12-10 2024-06-13 Merck Sharp & Dohme Llc Human mesothelin binders
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL148079A0 (en) * 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20110166335A1 (en) 2000-06-30 2011-07-07 Corbin David R Xenorhabdus sp. genome sequences and uses thereof
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
US20090252741A1 (en) 2004-09-08 2009-10-08 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
CN104968364A (zh) 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
WO2015092394A1 (en) 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
PT3151921T (pt) * 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
CN108271359B (zh) * 2015-02-13 2021-11-09 索伦托药业有限公司 结合ctla4的抗体治疗剂
TN2017000440A1 (en) 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
MA44594B1 (fr) * 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
FI3389699T3 (fi) 2015-12-15 2024-05-28 Oncoc4 Inc Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
SG10201603721TA (en) * 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
CN120173123A (zh) 2017-02-27 2025-06-20 蜻蜓疗法股份有限公司 靶向caix、ano1、间皮素、trop2、cea或紧密连接蛋白-18.2的多特异性结合蛋白
US11643463B2 (en) * 2017-05-19 2023-05-09 Wuxi Biologics (Shanghai) Co., Ltd. Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
AU2019413366B2 (en) 2018-12-27 2025-06-05 Gigagen, Inc. Anti-CTLA-4 binding proteins and methods of use thereof
EP3914355A1 (en) 2019-01-21 2021-12-01 Sanofi Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers
CA3184082A1 (en) 2020-07-02 2022-01-06 David Scott Johnson Anti-ctla-4 binding proteins and methods of use thereof

Also Published As

Publication number Publication date
JP7558949B2 (ja) 2024-10-01
JP2022516071A (ja) 2022-02-24
AU2019413366A1 (en) 2021-08-12
IL284156B1 (en) 2024-12-01
WO2020140084A1 (en) 2020-07-02
IL316757A (en) 2025-01-01
IL284156A (en) 2021-08-31
AU2019413366B2 (en) 2025-06-05
MX2021007848A (es) 2021-10-26
IL284156B2 (en) 2025-04-01
US20220064303A1 (en) 2022-03-03
JP7745669B2 (ja) 2025-09-29
CN114008071A (zh) 2022-02-01
AU2025223772A1 (en) 2025-09-18
KR20210121045A (ko) 2021-10-07
CA3124961C (en) 2025-11-25
EP3902821A4 (en) 2022-11-30
JP2025128343A (ja) 2025-09-02
EP3902821A1 (en) 2021-11-03
US12421311B2 (en) 2025-09-23
BR112021012588A2 (pt) 2021-09-08
SG11202106764YA (en) 2021-07-29
CN114008071B (zh) 2025-01-21
CA3249127A1 (en) 2026-03-02
CA3124961A1 (en) 2020-07-02
JP2024042072A (ja) 2024-03-27

Similar Documents

Publication Publication Date Title
CN114008071B (zh) 抗ctla-4结合蛋白及其使用方法
US20220064302A1 (en) Anti-PD-1 Binding Proteins and Methods of Use Thereof
WO2020140094A1 (en) Anti-b7-h3 binding proteins and methods of use thereof
CN116234821B (zh) 抗ctla-4结合蛋白和其使用方法
WO2020142626A1 (en) Anti-ox40 binding proteins and methods of use thereof
WO2022006555A2 (en) BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
US20220056137A1 (en) Anti-PD-L1 Binding Proteins and Methods of Use Thereof
WO2020140070A1 (en) Anti-b7-h4 binding proteins and methods of use thereof
CN117979995A (zh) 抗ctla-4结合蛋白及其使用方法
JP7854093B2 (ja) 抗ｃｔｌａ－４結合タンパク質およびその使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination